These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17372715)

  • 1. [Stress proteins in prostate cancer. Challenge and promise].
    Hadaschik BA; Melchior SW; Sowery RD; So AI; Gleave ME
    Urologe A; 2007 May; 46(5):516-20. PubMed ID: 17372715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of stress proteins in prostate cancer.
    So A; Hadaschik B; Sowery R; Gleave M
    Curr Genomics; 2007 Jun; 8(4):252-61. PubMed ID: 18645594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer.
    Ischia J; Saad F; Gleave M
    Curr Opin Urol; 2013 May; 23(3):194-200. PubMed ID: 23385973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the heat shock response and molecular chaperones in oncogenesis and cell death.
    Jolly C; Morimoto RI
    J Natl Cancer Inst; 2000 Oct; 92(19):1564-72. PubMed ID: 11018092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the apoptosis pathway in prostate cancer.
    Zielinski RR; Eigl BJ; Chi KN
    Cancer J; 2013; 19(1):79-89. PubMed ID: 23337761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer.
    Miyake H; Hara I; Fujisawa M; Gleave ME
    Expert Opin Investig Drugs; 2006 May; 15(5):507-17. PubMed ID: 16634689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers.
    Gleave M; Chi KN
    Ann N Y Acad Sci; 2005 Nov; 1058():1-15. PubMed ID: 16394121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-generation antisense drug for prostate cancer.
    Kerr C
    Lancet Oncol; 2004 Nov; 5(11):646. PubMed ID: 15536686
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.
    Muhammad LA; Saad F
    Expert Rev Anticancer Ther; 2015; 15(9):1049-61. PubMed ID: 26313417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer.
    Gleave M; Nelson C; Chi K
    Curr Drug Targets; 2003 Apr; 4(3):209-21. PubMed ID: 12643471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression.
    Miyake H; Hara I; Kamidono S; Gleave ME; Eto H
    Oncol Rep; 2003; 10(2):469-73. PubMed ID: 12579291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review).
    Magadoux L; Isambert N; Plenchette S; Jeannin JF; Laurens V
    Int J Oncol; 2014 Sep; 45(3):919-28. PubMed ID: 24969394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
    Rocchi P; So A; Kojima S; Signaevsky M; Beraldi E; Fazli L; Hurtado-Coll A; Yamanaka K; Gleave M
    Cancer Res; 2004 Sep; 64(18):6595-602. PubMed ID: 15374973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer.
    Uzzo RG; Haas NB; Crispen PL; Kolenko VM
    Cancer; 2008 Apr; 112(8):1660-71. PubMed ID: 18278811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53INP1 as new therapeutic target in castration-resistant prostate cancer.
    Giusiano S; Baylot V; Andrieu C; Fazli L; Gleave M; Iovanna JL; Taranger-Charpin C; Garcia S; Rocchi P
    Prostate; 2012 Sep; 72(12):1286-94. PubMed ID: 22213058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents.
    Gabai VL; Budagova KR; Sherman MY
    Oncogene; 2005 May; 24(20):3328-38. PubMed ID: 15735699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clusterin and IGFBPs as antisense targets in prostate cancer.
    Gleave M; Jansen B
    Ann N Y Acad Sci; 2003 Dec; 1002():95-104. PubMed ID: 14751827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
    BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 70 kilodalton heat shock protein is an inhibitor of apoptosis in prostate cancer.
    Jones EL; Zhao MJ; Stevenson MA; Calderwood SK
    Int J Hyperthermia; 2004 Dec; 20(8):835-49. PubMed ID: 15764345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat shock proteins in cancer: targeting the 'chaperones'.
    Nahleh Z; Tfayli A; Najm A; El Sayed A; Nahle Z
    Future Med Chem; 2012 May; 4(7):927-35. PubMed ID: 22571616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.